103 TCOG103 0211

*

*

103*

2 8 2/115 7 7/7~7/9 7~99~1010 11 104()

971028*

8122228315*

11037710379 711

*

210379 63010310

*

1*

*

2103*

*

*

*

*

101 1 102 12 101 1 103 2

15001500()

*

*

3 3 12 5 3 (1) 26 (1)

*2.14.3

1.11.21.32.12.22.33.13.2.13.2.23.2.3 3.33.43.53.73.83.93.63.104.14.24.34.44.55.15.25.3

*103

*

1.1Rating D Rating C Rating C 75%

*

1.1Rating B CRating A B

*

1.1

*

1.1

12

*

*

1.2Rating D Rating C

Rating C Rating B C

*

*

1.21

2

*

1.21234567

*

1.3Rating D Rating C Rating C

*

1.3Rating B C12

Rating A B

*

1.3

1[ ]

23.1

*103

*

2.1Rating D Rating C

Rating C

Rating B C95%

*

2.1Rating A B3,0001 3,0002

98%

*

2.1111,1001.12

B1

99~101

*

2.1103100

*

2.2Rating D Rating C

Rating C

Rating B C

Rating A B

*

2.2

*

2.21234

123 Class1~2

*

2.2 ( ) 123

1,500Class1~2501,500 Class1~2125

*

2.2 23

*

1002.257584.2.1.11931942.3.261614.3.42662732.678814.3.72782852.883864.3.10290297

*

2.1290974.3.12/3003073.4T1171194.3.153123193.5N1201215.13213283.6M1221235.2329330

*

3.71241268.113763783.10T1291318.223793813.11N1321338.333823843.12M1341358.443853873.131361388.55388390

*

3.191491528.663913934.1.21751828.773943964.1.41851868.883973994.1.51871878.99400402

*

2.3Rating D80%Rating C80% 85%Rating B85%95%Rating A95%Stage

*

2.3

*

2.3

*

2.3

*

1002.13Tumor Size96983.10T Pathologic T1271292.14Regional Lymph Nodes Examined991003.11NPathologic N1301312.15Regional Lymph Nodes Positive1011023.12 MPathologic M132133

*

3.4T Clinical T1151173.13Pathologic Stage Group1341363.5NClinical N118119Other Staging System FIGO3.6MClinical M120121Other Staging SystemBCLC3.7Clinical Stage Group122124Other Staging System histology

*103

C18 - C21C22C33 - C34C50C53C54C56C00 - C06C09 - C10C12 - C14 )C11C15C16C61C67M-code 9590 9992)

*

*

3.11,500Rating D Rating C Rating C275%1,500Rating D Rating C Rating C275%

*

3.1Rating B CRating C

85%

75%Rating B C

85%

75%

*

3.1Rating A B85%Rating A B85%

*

3.1 /

*

3.1Class 0~3501 peer review article 234

*

3.1minimum requirement12345comorbidity6 regimens dose

12

*

3.1123 Major Modality4

*

3.1

*

3.11Class 1~2 I~III ()

*

3.12

3

41/3

/ 1,500 / 1,500 6 8 3,00012 8 10 3,00015

*

3.23.2.1Rating D70%

Rating C70%80%

Rating B80%90%

Rating A90%

*

3.2.112

Initial StageAJCC

*

3.2.19911AJCCTNM

103CP

*

3.2.1 100%

12 10 2 2 210 + 02/212 100%20 / 24 100%83.33%=83.3% Rating B

3.1

*

3.2.2Rating D60%Rating C60%75%Rating B75%85%Rating A85%123 Gr. III

*

3.2.250CAF x 63weekly Toxicity Checking List

*

3.2.2

8 4 3 1 2 3 1 34 + 21 + 13/38 100%17 / 24 100%70.83% =70.8% Rating C

3.1

*

3.2.3Rating D70%

Rating C70%80%

Rating B80%90%

Rating A90%123

*

3.2.3 Neoadjuvant Complete Response Complete RemissionCRNo Evidence of DiseaseNED

*

3.2.3

8 4 3 3 2 1 1 34 + 23 + 11/38 100%19/24 100%79.17%=79.2%Rating C

3.1

*

3.31,500Rating D Rating C Rating C 10%1,500Rating D Rating C Rating C 10%

*

3.3Rating B C15% 10%60%Rating B C15% 10%60%

*

3.3Rating A B 20%15%80%80%Rating A B20% 15%80%80%Class 0~3500

*

3.3

Class 0~350

*

3.3

90%

1 ~ 49 1 50 2

*

3.3

*

3.3123

1234

*

3.3 Class 1~3

1conclusion or recommendation2process

*

3.31 302 30

*

2. 3. 4.

*

*

9. 10.11.12.

*

*

3.4Rating D Rating C

Rating CPrescription2

*

3.4Rating B C Rating C 80%

Rating A B Rating C

*

3.4/

*

3.4Class 0~3501peer review article234

*

3.4AdjuvantNeoadjuvantConcurrent ChemoradiotherapyCCRT RegimenPrescription

*

3.5Rating D Rating C

Rating C

Rating B C

*

3.5Rating A B

*

3.5 123

*

3.5

ITIntrathecalTACETranseatheter Arterial Chemoembolization

Near missing near missing

*

3.6Rating D Rating C

Rating C

*

3.6Rating B C

Rating A B80%

*

3.612

*

3.613623

*

3.6

123

12 1 3 4

*

3.6spill kits

1

*

3.62 6103

*

3.7Rating D Rating C

Rating C

*

3.7Rating B C

*

3.7Rating A B

*

3.7

*

3.712

Permanent Section

*

3.7

1 2

*

3.712 BCAPTAF

*

3.8 Rating D Rating C

Rating C1

Rating B C

*

3.8Rating A B

90%

*

3.8 CT MRI

*

3.8

*

3.9Rating D Rating C Rating C Curative Intent 1 2

80%

*

3.9Rating B C Rating C

90%

80%

*

3.9Rating A B Rating C

90%

*

3.9

*

3.91 2CTVPTV5%CTV66.6 Gy/37 fxrange63~70.2 Gy/35~39 fx

*

3.91peer review article

2

3

4

*

3.9 curative intent1 2

*

3.9 1 treatment planningverification 2 7.

*

3.9 CD

3.1 6 1/3

*

3.101,500Rating D Rating C Rating C61,500Rating D Rating C Rating C8

*

3.10Rating BCRating C2Rating A B4Rating BCRating C4Rating A B6

*

3.10 Rating B2/4

*103

*

4.11234Rating D Rating C Rating C1Rating B CRating A B

*

4.1/1 peer review article 234

*

4.1Port-AHickmanPICC3.6

*

4.2Rating D Rating C

Rating C

Rating B C

Rating A B

*

4.2 123

*

4.2341 3.6

*

4.3Rating D Rating C Rating CRating B C 50 %Rating A C 60 %

*

4.3

*

4.3 C00-C97ICD-10140-208ICD-9

*

4.4Rating D Rating C Rating C3400

*

4.4Rating B C Rating A B350

*

4.4103100Class 12Class 0

*

4.41

*

4.42A2palliative treatment

*

4.4

*

NClass 12

*

4.5Rating D Rating C Rating CRating B C

*

4.5Rating A B

*

4.5

*

4.5

AintakeBMI

*103

*

5.1Rating D Rating C Rating C Rating B CRating A B

*

5.1 2

*

5.2Rating D Rating C

Rating C

Rating B C

Rating A B

*

5.2

*

5.3 A

*

5.3

*

************************************************************************************************************************ *